3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Breast Neoplasms
10
Pain, Postoperative
9
Neoplasms
9
Parkinson Disease 4, Autosomal Dominant Lewy Body
8
Lung Neoplasms
8
Stomach Neoplasms
6
Colonic Neoplasms
6
Brain Neoplasms
6
Thyroid Neoplasms
5
Prostatic Neoplasms
5
Colorectal Neoplasms
5
Agnosia
4
Thromboembolism
3
Pain
3
Ovarian Neoplasms
3
Myofibroma
3
Head and Neck Neoplasms
3
Depression
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma, Hepatocellular
3
Uterine Neoplasms
2
Urinary Bladder Neoplasms
2
Supratentorial Neoplasms
2
Neoplasm Metastasis
2
Leiomyoma
2
Hemangioma
2
Arthritis, Rheumatoid
2
Vomiting
1
Visceral Pain
1
Uterine Cervical Neoplasms
1
Interventions
Paclitaxel
16
Carboplatin
14
Cisplatin
12
Oxaliplatin
9
Hyperthermic Intraperitoneal Chemotherapy
9
Cytoreduction Surgical Procedures
9
Fluorouracil
7
Bevacizumab
7
Doxorubicin
5
Leucovorin
4
Gemcitabine
4
catumaxomab
3
Docetaxel
3
Albumin-Bound Paclitaxel
3
130-nm albumin-bound paclitaxel
3
nintedanib
2
liposomal doxorubicin
2
epothilone B
2
Surgical Procedures, Operative
2
Palliative Care
2
Mitomycin
2
Laparoscopy
2
Interviews as Topic
2
Drug Therapy
2
Blood Specimen Collection
2
veliparib
1
tremelimumab
1
talimogene laherparepvec
1
strattice
1
sodium thiosulfate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Peritoneal Neoplasms
×
Saline Solution
×
Clear all
NCT03740165
2026-05-04
KEYLYNK-001
Merck Sharp & Dohme LLC
Phase 3
Completed
1,367 enrolled
29 charts